The foundation of everything GBS represented spoke volumes to the impact they could make both in research but also response for Patients today who suffer. How rare to find organizations focused on every impacting opportunities whereby they can make a difference for their Patients and those who Provide care with consideration from propagation to Patient.
GBS has established an incredible pipeline of development formulations, based on novel medications founded in their patent pending formula’s utilizing Cannabis compounds. Their mission is clear at every pain point, GBS is hyper focused to become the future of healing. GBS is at the forefront of this discipline and a humbling labor of love by those in research who seek to solve some of the greatest challenges of our time, Patients health and wellness as diseases and indications increase and evolve.
Certainly a standout of noteworthiness was the scientific talent GBS has been able to traction in the process, establishing themselves as a key competitor with a strong advantage in the genetics, positioning themselves with Louisiana State University Agricultural Center, an industry leader in developing proprietary genetics preserving the consistency and character of these compounds.
GBS has filed their first patent application containing mixtures of complex cannabis compounds designed to impact many neurological disorders, understanding the vast Patient obstacle found in medication resistance to traditional medications. The powerful aspect GBS maintains is the progressive posture necessary facilitating the opportunity to discover and deliver precision medications laying the future groundwork of care in health and wellness, today!
CEO John Poss — GB is "Small but Complex"
Neuro Research
98